Unveiling 6 Analyst Insights On Harmony Biosciences
Unveiling 6 Analyst Insights On Harmony Biosciences
揭示關於harmony biosciences的6位分析師見解
In the preceding three months, 6 analysts have released ratings for Harmony Biosciences (NASDAQ:HRMY), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中，有6位分析師發佈了Harmony Biosciences（納斯達克股票代碼：HRMY）的評級，提出了從看漲到看跌的各種觀點。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Harmony Biosciences, presenting an average target of $52.0, a high estimate of $56.00, and a low estimate of $48.00. This current average has not changed from the previous average price target.
在評估12個月目標股價時，分析師公佈了對Harmony Biosciences的見解，平均目標股價爲52.0美元，最高估計爲56.00美元，低估值爲48.00美元。當前的平均價格與之前的平均目標價格沒有變化。
Diving into Analyst Ratings: An In-Depth Exploration
深入分析師評級：深度探索
In examining recent analyst actions, we gain...
在研究分析師最...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。